検索結果

４解析データの準備·································································································································1 ５統計解析···················································································································································2 ６その他························································································································································2 Ⅱ結果の概要 １解析対象者··············································································································································4 ２標準化該当比の地理的分布 (1)メタボリックシンドローム再判定···································································································5 (2)肥満（BMI25kg/㎡以上かつ腹囲基準値以上）の者·····························································6 (3)腹囲基準値以上の者······················································································································6 (4) BMI25 kg/㎡以上の者····················································································································7 (

https://www.pref.saitama.lg.jp/documents/188998/r2_zentai.pdf種別：pdf サイズ：3426.49KB

４解析データの準備····································································································································2 ５統計解析······················································································································································3 ６その他···························································································································································3 Ⅱ結果の概要 １解析対象者···············································································································································6 ２標準化該当比の地理的分布 （1）メタボリックシンドローム再判定···································································································7 （2）肥満（BMI25 kg/㎡以上かつ腹囲基準値以上）の者···························································8 （3）腹囲基準値以上の者······················································································································8 （4）BMI25 kg/㎡以上の者····················································································································

https://www.pref.saitama.lg.jp/documents/188998/r3_kyoukaikenpo-kokuho.pdf種別：pdf サイズ：5355.094KB

４解析データの準備·································································································································1 ５統計解析··················································································································································2 ６その他························································································································································2 Ⅱ結果の概要 １解析対象者··············································································································································4 ２標準化該当比の地理的分布 (1)メタボリックシンドローム再判定···································································································5 (2)肥満（BMI25kg/㎡以上かつ腹囲基準値以上）の者·····························································6 (3)腹囲基準値以上の者······················································································································6 (4) BMI25 kg/㎡以上の者····················································································································7 (

https://www.pref.saitama.lg.jp/documents/188998/r3_zentai.pdf種別：pdf サイズ：3750.437KB

４解析データの準備····································································································································2 ５統計解析······················································································································································3 ６その他···························································································································································3 Ⅱ結果の概要 １解析対象者···············································································································································6 ２標準化該当比の地理的分布 （1）メタボリックシンドローム再判定···································································································7 （2）肥満（BMI25 kg/㎡以上かつ腹囲基準値以上）の者···························································8 （3）腹囲基準値以上の者······················································································································8 （4）BMI25 kg/㎡以上の者····················································································································

https://www.pref.saitama.lg.jp/documents/188998/r4_kyoukaikenpo-kokuho.pdf種別：pdf サイズ：5292.028KB

４解析データの準備·································································································································1 ５統計解析··················································································································································2 ６その他························································································································································2 Ⅱ結果の概要 １解析対象者··············································································································································4 ２標準化該当比の地理的分布 (1)メタボリックシンドローム再判定···································································································5 (2)肥満（BMI25kg/㎡以上かつ腹囲基準値以上）の者····························································6 (3)腹囲基準値以上の者······················································································································6 (4) BMI25 kg/㎡以上の者····················································································································7 (

https://www.pref.saitama.lg.jp/documents/188998/r4_zentai.pdf種別：pdf サイズ：2435.523KB

中のその他の元素不純物と共に遊離してきた不純物である可能性、並びにそれら元素の実際の天然存在量及び環境分布が挙げられる。 本ガイドラインにおいては、その目的を踏まえ、天然存在量が低い元素とは、天然存在量がSi原子106

https://www.pref.saitama.lg.jp/documents/190179/r020626betten.pdf種別：pdf サイズ：880.706KB

施することができる場合」とは、例えば、治験の方法（評価項目等を含む）が簡単であり、参加実施医療機関の数及び地域的分布が大規模であるなどのために実施医療機関等への訪問によるモニタリングが困難である治験において、治験責

https://www.pref.saitama.lg.jp/documents/190179/sannkou-gaidannsu.pdf種別：pdf サイズ：709.543KB

注意 15.1臨床使用に基づく情報 15.2非臨床試験に基づく情報 16.薬物動態 16.1血中濃度 16.2吸収 16.3分布 16.4代謝 16.5排泄 （別紙１） 16.6特定の背景を有する患者 16.7薬物相互作用 16.8その他 17.臨床成績 17.1有効性及び安全性に関

https://www.pref.saitama.lg.jp/documents/190179/yakuseiannhatu0608dai1gou_kaiseigo.pdf種別：pdf サイズ：519.015KB

注意 15.1臨床使用に基づく情報 15.2非臨床試験に基づく情報 16.薬物動態 16.1血中濃度 16.2吸収 16.3分布 16.4代謝 16.5排泄 16.6特定の背景を有する患者 16.7薬物相互作用 16.8その他 17.臨床成績 17.1有効性及び安全性に関する試

https://www.pref.saitama.lg.jp/documents/190179/yakuseihatu0608dai1gou_kaiseigo.pdf種別：pdf サイズ：436.231KB

は性能を発揮すると考えられる原理・メカニズムを簡潔に記載すること。 （13）体内動態当該再生医療等製品の生体内分布、生着期間又は効果持続期間等について知見を集積した場合は記載すること。 （14）「貯蔵方法及び有効期間等」について

https://www.pref.saitama.lg.jp/documents/190179/yakusyokuannhatu1002dai13gou_kaiseigo.pdf種別：pdf サイズ：252.495KB